Bryan, Garnier & Co's News

A more focused Sanofi is on the way

FV EUR83 vs. EUR86 NEUTRAL
News published on
May Monday 30, 2016


Sanofi is currently working on reinforcing its strategic franchises which are set to drive growth into the next decade. The established products will progressively decline whereas the Diabetes/CV GBU will be highly dependent on Praluent. We see the trajectory as positive, believing that it could ultimately open the way to a new and compelling investment case.  That said, it is still a tad early in our view.


For more information, please contact marketing@bryangarnier.com